Connecticut is home to 49 bioscience companies, with 30+ located in the Greater New Haven region. Anchored by scientific research at Yale, the region’s bioscience cluster includes both large pharmaceutical companies and small startups, developing new drugs, therapies and medical devices. These businesses often tend to feed from the research and innovation ties with higher learning institutions, chemical manufacturing (e.g. pharmaceuticals) and healthcare (medical research). With a state wide priority focus on biosciences, the South Central Connecticut region is ground zero for biosciences infrastructure of skilled scientists, technicians, lab space, plus a supplier network for everything from rubber gloves to medical-waste disposal. Much of the lab space is in proximity to Yale, the epicenter of pharmacological and medical research in Connecticut. These include Science Park, New Haven's oldest lab-incubator complex and Yale's 136-acre bioscience park, as well as 300 George St., a one-time phone company building converted to office-lab space now teeming with bioscience tenants.
- Originally a Yale start-up, the company is returning to New Haven with 300 jobs (and adding 300 new jobs) at a 425,000 s.f. building now under construction in the medical district. The $100+ million investment is the first project at Downtown Crossing, one of the nation’s largest highway removal and redevelopment projects. The facility opened in January 2016.
- Forbes® The World's Biggest Public Companies 2,000 (#1235 in 2016)
- In 2015, Covidien was acquired by Medtronic - press release
- One of the region’s largest employers also relocated Covidien Surgical Devices (400 additional employees) to New Haven in 2010. The new division annual provides training on its new equipment to 900 physicians.
- Forbes® World’s Most Innovative Companies 2013 ranked Covidien Public Limited Company #67 (location in North Haven)
The laboratory processes approximately 50,000 samples per year.